

## ShareCafé Small Cap “Hidden Gems” Webinar Presentation

Antisense Therapeutics (ASX:ANP | US OTC:ATHJY) is pleased to announce its participation in the ShareCafé Small Cap “Hidden Gems” Webinar to be held on Friday 26<sup>th</sup> June 2020 at 12.30pm AEST.

Managing Director Mark Diamond will provide an update on the Company with a focus on its Duchenne Muscular Dystrophy (DMD) program and the recently reported highly promising results from a Phase II clinical trial in boys with DMD.

The free webinar is able to be viewed live via Zoom over the internet. To access further details of the event and to register, please click on the following link or copy and paste into your internet browser.

[https://us02web.zoom.us/webinar/register/WN\\_QyDqOvS6RR-lvdndvTuLDw](https://us02web.zoom.us/webinar/register/WN_QyDqOvS6RR-lvdndvTuLDw)

A recorded copy of the webinar will be made available following the event.

Authorised for release by the Managing Director.

### For more information please contact:

#### Antisense Therapeutics

Mark Diamond  
Managing Director  
+61 (0)3 9827 8999  
[www.antisense.com.au](http://www.antisense.com.au)

#### Investment Enquiries

Gennadi Koutchin  
XEC Partners  
[gkoutchin@xecpartners.com.au](mailto:gkoutchin@xecpartners.com.au)  
+61 423 500 233

**About Antisense Therapeutics** is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHR production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.